Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.44 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22550528 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL20718429 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL10192028 | 0.87 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL22550478 | 0.86 | MAPT (0.53) | SMN1; SMN2NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL22550484 | 0.86 | MAPT (0.53) | SMN1; SMN2NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL22550504 | 0.86 | MAPT (0.53) | SMN1; SMN2NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL22550479 | 0.85 | LMNA (0.58) | SMN1; SMN2NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL20718275 | 0.85 | LMNA (0.58) | SMN1; SMN2NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL22550456 | 0.85 | LMNA (0.58) | SMN1; SMN2NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL20718372 | 0.84 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200325177-A1 | METHODS OF MAKING STREPTOGRAMIN COMPOSITIONS AND THE USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-10-15 | — | — | US | disclosed |
| WO-2019028084-A1 | METHODS OF MAKING STREPTOGRAMIN COMPOSITIONS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325177-A1 | METHODS OF MAKING STREPTOGRAMIN COMPOSITIONS AND THE USE THEREOF | PLG, LIPA, MB | SMN1; SMN2 3525/4885NPC1 2832/4885RAB9A 3115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.